Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000163561 | SCV000214119 | likely benign | Hereditary cancer-predisposing syndrome | 2014-09-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000589682 | SCV000517874 | likely benign | not provided | 2021-03-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000459412 | SCV000562585 | likely benign | Familial adenomatous polyposis 1 | 2025-01-12 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000163561 | SCV000687152 | likely benign | Hereditary cancer-predisposing syndrome | 2016-11-22 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000443758 | SCV000694128 | likely benign | not specified | 2019-11-17 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000459412 | SCV000786013 | likely benign | Familial adenomatous polyposis 1 | 2018-02-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000589682 | SCV000805473 | likely benign | not provided | 2017-11-10 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000589682 | SCV001471958 | likely benign | not provided | 2020-06-09 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000459412 | SCV004018712 | benign | Familial adenomatous polyposis 1 | 2023-02-17 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |
All of Us Research Program, |
RCV003995262 | SCV004837325 | likely benign | Classic or attenuated familial adenomatous polyposis | 2023-12-01 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000589682 | SCV000591053 | likely benign | not provided | no assertion criteria provided | clinical testing | The p.Gly263Gly variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. The variant was identified in the ClinVar database (classified as “likely benign” by Ambry Genetics), and in the Exome Aggregation Consortium (ExAC) database where it was present at a very low frequency in a population of European individuals (4/66322 chromosomes, or frequency of 0.00006). The variant was not identified in the literature, nor was it identified in any of the following databases: dbSNP, NHLBI Exome Sequencing Project (Exome Variant Server), COSMIC, InSiGHT Colon Cancer Gene Variant Database, “Zhejiang Colon Cancer Database”, GeneInsight COGR database, and UMD. In silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict the creation of a cryptic splice site. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as predicted benign. |